Author Topic: (Abst.) Tysabri better than Gilenya in achieving "no evidence of disease activity"  (Read 56 times)

0 Members and 1 Guest are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9821
  • MS diagnosed 1980
  • Location: Pacific Northwest

From PubMed (October 30, 2020), "BEST-MS:  A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS":


https://pubmed.ncbi.nlm.nih.gov/33124504/
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
71 Views
Last post April 26, 2017, 09:53:18 am
by agate
0 Replies
176 Views
Last post August 22, 2017, 05:52:26 am
by agate
0 Replies
91 Views
Last post June 12, 2018, 09:18:55 pm
by agate
0 Replies
43 Views
Last post September 11, 2022, 08:55:48 pm
by agate
0 Replies
41 Views
Last post December 07, 2022, 10:42:38 am
by agate